Taylor Hoffman Wealth Management Has $1.30 Million Stock Position in Merck & Co., Inc. (NYSE:MRK)

Share on StockTwits

Taylor Hoffman Wealth Management increased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 24.2% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 15,380 shares of the company’s stock after buying an additional 3,000 shares during the period. Taylor Hoffman Wealth Management’s holdings in Merck & Co., Inc. were worth $1,295,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Titan Capital Management LLC CA acquired a new position in Merck & Co., Inc. during the 2nd quarter valued at about $25,000. LFA Lugano Financial Advisors SA lifted its position in Merck & Co., Inc. by 250.0% during the 2nd quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock valued at $26,000 after purchasing an additional 225 shares during the period. JJJ Advisors Inc. acquired a new position in Merck & Co., Inc. during the 2nd quarter valued at about $27,000. Cumberland Partners Ltd acquired a new position in Merck & Co., Inc. during the 2nd quarter valued at about $40,000. Finally, Fusion Family Wealth LLC lifted its position in Merck & Co., Inc. by 268.2% during the 2nd quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock valued at $41,000 after purchasing an additional 354 shares during the period. Institutional investors and hedge funds own 74.95% of the company’s stock.

A number of research analysts have issued reports on MRK shares. Mizuho upped their target price on shares of Merck & Co., Inc. from $97.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Bank of America started coverage on shares of Merck & Co., Inc. in a research report on Wednesday, October 16th. They set a “neutral” rating and a $90.00 target price on the stock. Leerink Swann started coverage on shares of Merck & Co., Inc. in a research report on Thursday, August 15th. They set an “outperform” rating and a $103.00 target price on the stock. Argus upped their target price on shares of Merck & Co., Inc. to $105.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. set a $96.00 target price on shares of Merck & Co., Inc. and gave the company a “buy” rating in a research report on Thursday, October 10th. One research analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $95.13.

Shares of NYSE:MRK traded up $0.71 during mid-day trading on Friday, reaching $83.59. The stock had a trading volume of 6,053,527 shares, compared to its average volume of 10,105,755. The firm has a market cap of $212.31 billion, a PE ratio of 19.26, a price-to-earnings-growth ratio of 1.80 and a beta of 0.54. The firm has a 50 day simple moving average of $84.01 and a two-hundred day simple moving average of $82.77. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 0.82. Merck & Co., Inc. has a twelve month low of $70.89 and a twelve month high of $87.35.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $1.51 earnings per share for the quarter, beating analysts’ consensus estimates of $1.24 by $0.27. The business had revenue of $12.40 billion for the quarter, compared to the consensus estimate of $11.59 billion. Merck & Co., Inc. had a net margin of 20.26% and a return on equity of 47.94%. Merck & Co., Inc.’s revenue for the quarter was up 14.9% on a year-over-year basis. During the same period last year, the company posted $1.19 EPS. On average, equities analysts anticipate that Merck & Co., Inc. will post 5.16 EPS for the current fiscal year.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Story: What is a Tariff?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.